Only in Titles

           Search results for: FDA    

paperclip

#32084607   // Save this To Up

Systematic Review and Meta-analysis to Estimate the Antibacterial Treatment Effect of Nitrofurantoin for a Non-Inferiority Trial in Uncomplicated Urinary Tract Infection.

Active-comparator, non-inferiority study designs are used in uncomplicated urinary tract infection (uUTI) to establish the efficacy of a new antibacterial, given the availability of effective antibiotics. We estimate the treatment effect of a planned antimicrobial comparator (nitrofurantoin), from historical trial data, to properly design an upcoming non-inferiority study in uUTI.

2877 related Products with: Systematic Review and Meta-analysis to Estimate the Antibacterial Treatment Effect of Nitrofurantoin for a Non-Inferiority Trial in Uncomplicated Urinary Tract Infection.

FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu Analysis Tool for Custom Analysis Tool for AAH-CYT Analysis Tool for AAH-CYT Analysis Tool for AAH-INF Analysis Tool for AAM-ANG Analysis Tool for AAM-CYT Analysis Tool for AAM-INF Toxoplasma gondii GRA8, r

Related Pathways

paperclip

#32084595   // Save this To Up

Clinicians' Perspective of The New Pregnancy and Lactation Labeling Final Rule (PLLR): Results from an AAAAI/FDA Survey.

On June 30, 2015, the U.S. Food and Drug Administration (FDA) began implementation of the PLLR, which replaced the pregnancy letter category system (A, B, C, D or X) with integrated narrative summaries of the risks of using a drug or biological product during pregnancy and lactation. The letter category system, first established in 1979, was regarded as overly simplistic and misinterpreted as a grading system. The PLLR labeling format was created to improve the presentation of available data on use of the drug during pregnancy and/or lactation, OBJECTIVE: Survey clinician awareness, assessment, and use of this new labeling format METHODS: In January 2018, an online survey, developed in collaboration between the American Academy of Allergy, Asthma & Immunology (AAAAI) and the U.S. FDA, was sent to a random sample of the U.S. membership of the AAAAI. The survey content consisted of questions addressing the following: demographics, awareness and use of the PLLR, and value and understanding of the PLLR format based on an example of the pregnancy subsection of labeling.

2403 related Products with: Clinicians' Perspective of The New Pregnancy and Lactation Labeling Final Rule (PLLR): Results from an AAAAI/FDA Survey.

FDA Standard Frozen Tissu Androgen Receptor Antibod ∆1-Androstene-3β,17β- Andarine C19H18F3N3O6� Anti Androgen Receptor pr Goat Anti-Human Androgen FDA Standard Frozen Tissu ChromaLink™ Digoxigenin Androgen Receptor , Mouse FDA normal and tumor orga MarkerGeneTM TAMRA Antibo Normal rat multiple organ

Related Pathways

paperclip

#32084316   // Save this To Up

Discover 4,6-O-thenylidene-β-D-glucopyranoside-(2″-acetamido, 3″-acetyl-di-S-5-fluorobenzothizole/5-fluorobenzoxazole)-4'-demethylepipodophyllotoxin as potential less toxic antitumor candidate drugs by reducing DNA damage and less inhibition of PI3K.

As FDA-approved drug, teniposide was utilized in cancer treatment but was accompanied by strong side effect in long-term clinical trials. This work discovered potential candidate drugs with low toxicity by modifying the molecule structure of teniposide through a structure-guided drug design approach. The IC50 value of novel 4,6-O-thenylidene-β-D-glucopyranoside-(2″-acetamido, 3″-acetyl-di-S-5-fluorobenzothizole/5-fluorobenzoxazole)-4'-demethylepipodophyllotoxin (compounds 15 and 16) was 120.4-125.1 µM, which was significantly improved by around 10 times than teniposide (11.5-22.3 µM) against human healthy cells (i.e., HL-7702, H8, MRC-5 and HMEC). In the in vivo studies demonstrated compounds 15 and 16 significantly suppressed the tumor growth in HepG2 cell xenograft model without exhibiting obvious toxicity (LD50 value of 208.45 and 167.52 mg/kg), which was lower than that of teniposide (LD50 value of 46.12 mg/kg). Compounds 15 and 16 caused mild γH2AX phosphorylation for low DNA toxicity and less inhibition of PI3K/Akt. Compounds 15 and 16 might be potential anti-tumor drugs with low toxicity.

1521 related Products with: Discover 4,6-O-thenylidene-β-D-glucopyranoside-(2″-acetamido, 3″-acetyl-di-S-5-fluorobenzothizole/5-fluorobenzoxazole)-4'-demethylepipodophyllotoxin as potential less toxic antitumor candidate drugs by reducing DNA damage and less inhibition of PI3K.

Benzyl 2-(Acetamido)-2-de Benzyl 2-Acetamido-2-deox Benzyl 2-Acetamido-6-O-be Benzyl 2-Acetamido-3-O-(2 Benzyl 2-(Acetamido)-2-de Benzyl 2-Acetamido-2-deox Benzyl 2-Acetamido-4,6-O- Benzyl 2-Acetamido-3,4-di Azido 2-Acetamido-2-deoxy Benzyl 2-(Acetamido)-2-de Allyl 2-Acetamido-3,4,6-t Benzyl 2-Acetamido-2-deox

Related Pathways